Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Inecalcitol, an analog of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system.

Ma Y, Yu WD, Hidalgo AA, Luo W, Delansorne R, Johnson CS, Trump DL.

Cell Cycle. 2013 Mar 1;12(5):743-52. doi: 10.4161/cc.23846.

2.

MART-10, a novel vitamin D analog, inhibits head and neck squamous carcinoma cells growth through cell cycle arrest at G0/G1 with upregulation of p21 and p27 and downregulation of telomerase.

Chiang KC, Yeh CN, Hsu JT, Chen LW, Kuo SF, Sun CC, Huang CC, Pang JH, Flanagan JN, Takano M, Kittaka A, Juang HH, Yang SW, Chen TC.

J Steroid Biochem Mol Biol. 2013 Nov;138:427-34. doi: 10.1016/j.jsbmb.2013.09.002.

PMID:
24044969
3.

1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model.

Ma Y, Yu WD, Hershberger PA, Flynn G, Kong RX, Trump DL, Johnson CS.

Mol Cancer Ther. 2008 Sep;7(9):3047-55. doi: 10.1158/1535-7163.MCT-08-0243.

4.

Inecalcitol, an analog of 1α,25(OH)(2) D(3) , induces growth arrest of androgen-dependent prostate cancer cells.

Okamoto R, Delansorne R, Wakimoto N, Doan NB, Akagi T, Shen M, Ho QH, Said JW, Koeffler HP.

Int J Cancer. 2012 May 15;130(10):2464-73. doi: 10.1002/ijc.26279.

6.

Regulation of motility, invasion, and metastatic potential of squamous cell carcinoma by 1α,25-dihydroxycholecalciferol.

Ma Y, Yu WD, Su B, Seshadri M, Luo W, Trump DL, Johnson CS.

Cancer. 2013 Feb 1;119(3):563-74. doi: 10.1002/cncr.27531.

7.

Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells.

Alagbala AA, Johnson CS, Trump DL, Posner GH, Foster BA.

Oncology. 2006;70(6):483-92.

PMID:
17237623
8.

Cell cycle arrest and apoptosis induced by 1α,25(OH)2D3 and TX 527 in Kaposi sarcoma is VDR dependent.

González-Pardo V, Suares A, Verstuyf A, De Clercq P, Boland R, de Boland AR.

J Steroid Biochem Mol Biol. 2014 Oct;144 Pt A:197-200. doi: 10.1016/j.jsbmb.2013.11.014. Review.

PMID:
24316429
9.

Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice.

Zinser GM, McEleney K, Welsh J.

Mol Cell Endocrinol. 2003 Feb 28;200(1-2):67-80.

PMID:
12644300
10.

The in vitro and in vivo antitumor effects of clotrimazole on oral squamous cell carcinoma.

Wang J, Jia L, Kuang Z, Wu T, Hong Y, Chen X, Leung WK, Xia J, Cheng B.

PLoS One. 2014 Jun 3;9(6):e98885. doi: 10.1371/journal.pone.0098885.

12.

Inhibition of protein kinase CK2 reduces Cyp24a1 expression and enhances 1,25-dihydroxyvitamin D(3) antitumor activity in human prostate cancer cells.

Luo W, Yu WD, Ma Y, Chernov M, Trump DL, Johnson CS.

Cancer Res. 2013 Apr 1;73(7):2289-97. doi: 10.1158/0008-5472.CAN-12-4119.

13.

A vitamin D receptor-alkylating derivative of 1α,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth.

Lambert JR, Eddy VJ, Young CD, Persons KS, Sarkar S, Kelly JA, Genova E, Lucia MS, Faller DV, Ray R.

Cancer Prev Res (Phila). 2010 Dec;3(12):1596-607. doi: 10.1158/1940-6207.CAPR-10-0122.

14.

Cooperative antitumor effects of vitamin D3 derivatives and rosemary preparations in a mouse model of myeloid leukemia.

Sharabani H, Izumchenko E, Wang Q, Kreinin R, Steiner M, Barvish Z, Kafka M, Sharoni Y, Levy J, Uskokovic M, Studzinski GP, Danilenko M.

Int J Cancer. 2006 Jun 15;118(12):3012-21.

15.

1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models.

Ma Y, Yu WD, Trump DL, Johnson CS.

Cancer. 2010 Jul 1;116(13):3294-303. doi: 10.1002/cncr.25059.

16.

Superagonistic action of 14-epi-analogs of 1,25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction.

Eelen G, Verlinden L, Rochel N, Claessens F, De Clercq P, Vandewalle M, Tocchini-Valentini G, Moras D, Bouillon R, Verstuyf A.

Mol Pharmacol. 2005 May;67(5):1566-73.

17.

1 Alpha,25-dihydroxyvitamin D3 and its TX527 analog inhibit the growth of endothelial cells transformed by Kaposi sarcoma-associated herpes virus G protein-coupled receptor in vitro and in vivo.

Gonzalez-Pardo V, Martin D, Gutkind JS, Verstuyf A, Bouillon R, de Boland AR, Boland RL.

Endocrinology. 2010 Jan;151(1):23-31. doi: 10.1210/en.2009-0650.

PMID:
19915163
18.

Antileukemic effect of a synthetic vitamin D3 analog, HY-11, with low potential to cause hypercalcemia.

Yoon JS, Kim JY, Park HK, Kim ES, Ahn KS, Yoon SS, Cho CG, Kim BK, Lee YY.

Int J Oncol. 2008 Feb;32(2):387-96.

PMID:
18202761
19.

Vitamin D analogue TX 527 down-regulates the NF-κB pathway and controls the proliferation of endothelial cells transformed by Kaposi sarcoma herpesvirus.

González-Pardo V, Verstuyf A, Boland R, Russo de Boland A.

Br J Pharmacol. 2013 Aug;169(7):1635-45. doi: 10.1111/bph.12219.

20.

In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma.

Luo Q, Hu D, Hu S, Yan M, Sun Z, Chen F.

BMC Cancer. 2012 Nov 14;12:517. doi: 10.1186/1471-2407-12-517.

Items per page

Supplemental Content

Support Center